Novel drug-eluting stents in the treatment of de novo coronary lesions

Capodanno, Davide; Dipasqua, Fabio; Tamburino, Corrado

doi:10.2147/vhrm.s11444

Cited by 11 publications

(6 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When BioMatrix Flex biolimus-eluting stent is compared the strut thickness 112 μm is much higher than 65 μm strut thickness. In this study, the MI (0%) and TLR (1.6%) significantly differ than MI with 7.0% (p < 0.001) and TLR with 7.8% (p < 0.01) of the BioMatrix stent [27] [28]. Hence, the Metafor SES with biodegradable polymer and thinner struts has potential to improve clinical outcomes.…”

Section: Discussionmentioning

confidence: 67%

Safety and Performance of Sirolimus-Eluting Coronary Stent System with Biodegradable Polymer: A Retrospective Analysis in Real-World Patient Population

Rao¹,

Rao²,

Kapardhi³

et al. 2017

WJCD

View full text Add to dashboard Cite

Background and Aim: Newer generation coronary stent systems with low profile metallic frame, biodegradable polymer coating and potent but safe anti-restenosis drug from "limus family" are emerging as safe and effective stents. To evaluate the safety and performance of Metafor SES (Meril life Sciences Pvt. Ltd., Vapi, India) in consecutive patients in a real-world population. Methods: The study was a retrospective, non-randomized, single-center study which evaluated the data of 127 patients who underwent percutaneous coronary intervention (PCI) treated with Metafor SES from February 2012 to February 2015 and mean follow-up period of those patients was 3.6 ± 0.6 years. The primary endpoint was a major adverse cardiac event (MACE) including cardiac death, myocardial infarction (MI), and target lesion revascularization (TLR). In addition, Stent thrombosis (ST) was analyzed at respective follow-up period. Results: A total of 127 patients (mean age: 53.70 ± 8.41 years and 99 males) were included. Among those 80 (63%) patients had hypertension and 58 (45.7%) patients with diabetes mellitus.At follow-up, MACE in form of TLR was observed in 2 (1.6%) patients only. No cardiac death or stent thrombosis was reported in any patient. A total of 169 lesions were treated with the Metafor SES (1.3 stents per lesion). The 38.4% of patients treated with the Metafor SES with lesion length ≥24 mm, and the procedural success was 100%. Conclusions: The lower incidence of MACE in uncontrolled and real world population at long term follow-up clearly depicts the prolonged safety and performance of the Metafor SES.

show abstract

Section: Discussionmentioning

confidence: 67%

Safety and Performance of Sirolimus-Eluting Coronary Stent System with Biodegradable Polymer: A Retrospective Analysis in Real-World Patient Population

Rao¹,

Rao²,

Kapardhi³

et al. 2017

WJCD

View full text Add to dashboard Cite

show abstract

“…Conor Medsystems (now part of Johnson & Johnson) developed cobalt-chromium stents with hundreds of laser cut reservoirs in the stent struts stents (Fig. 7b) [60,61]. The reservoirs are loaded with drug in a bioresorbable PLGA matrix.…”

Section: Implantable Deliverymentioning

confidence: 99%

“…At the end of the biodegradation process, only the bare metal stent remains. Stents containing various drugs, Nevo™ (sirolimus), CoStar™ (paclitaxel), Corio™ (pimecrolimus), and Symbio™ (paclitaxel and pimecrolimus in adjacent reservoirs), have been tested in clinical trials [60,61]. …”

Section: Implantable Deliverymentioning

confidence: 99%

Reservoir-based drug delivery systems utilizing microtechnology

Stevenson¹,

Santini²,

Langer

2012

Advanced Drug Delivery Reviews

201

126

View full text Add to dashboard Cite

This review covers reservoir-based drug delivery systems that incorporate microtechnology, with an emphasis on oral, dermal, and implantable systems. Key features of each technology are highlighted such as working principles, fabrication methods, dimensional constraints, and performance criteria. Reservoir-based systems include a subset of microfabricated drug delivery systems and provide unique advantages. Reservoirs, whether external to the body or implanted, provide a well-controlled environment for a drug formulation, allowing increased drug stability and prolonged delivery times. Reservoir systems have the flexibility to accommodate various delivery schemes, including zero order, pulsatile, and on demand dosing, as opposed to a standard sustained release profile. Furthermore, the development of reservoir-based systems for targeted delivery for difficult to treat applications (e.g., ocular) has resulted in potential platforms for patient therapy.

show abstract

“…Passive implantable drug delivery systems are driven by osmotic potential or diffusion. These microsystems have been employed in various applications such as ophthalmology [7][8][9][10][11][12][13], oncology [14][15][16], interventional cardiology [17][18][19][20], precocious puberty [7], acromegaly [21], Hepatitis C [21][22][23], prostate cancer [24][25][26], pain indications [27], type 2 diabetes and Hepatitis [28][29][30][31][32]. In contrast, active implantable drug delivery systems are driven by mechanical pumping [33,34], electrolysis [35], and other actuation methods, which enable the patient or physician to start/modify/stop drug release interactively.…”

Section: Introductionmentioning

confidence: 99%